The transparotid-cervical approach is the preferred procedure for most parapharyngeal tumors and can be combined with midline mandibulotomy for large vascular or selected malignant tumors. Recurrence after removal of pleomorphic adenomas is only 4%. Recurrent or persistent malignant disease is nearly always fatal. Perioperative mortality is zero, and morbidity is most often associated with cranial nerve neuropathy.
Hemangiopericytomas are rare tumors of vascular origin most commonly found in the extremities or retroperitoneal area. When they originatefrom the nasal cavity and paranasal sinuses, they tend to be less aggressive and generall.v do not metastasize. The term "hemangiopericytoma-like lesion" has been coined for sinonasal hemangiopericytomas that display more benign histologic and growth characteristics than do those located elsewhere. Fifteen cases of hemangiopericytoma of the nasal cavity and paranasal sinuses were reviewed over the period 1951 to 1990; included arefol/ow-up data on cases reported earlier from this institution. The clinical course, management, and outcome was evaluated and correlated with the histologic characteristics of the tumors. The recurrence rate in our series was 13.3%; the meanfol/ow-up was 11 years. No patients died of their disease or had evidence a/metastatic disease. This clinicopathologic review suggests that sinonasal hemangiopericytomas should not be classified as "hemangiopericytoma-like" lesions; rather, they should be expected to have significant local recurrence rates with low rates of distant metastasis and mortality. Long-term/ol/ow-up is essential as Rochester, Minnesota
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.